PACLITAXEL, ALPELISIB, DOXORUBICIN HYDROCHLORIDE, OLAPARIB, ALPELISIB, OLAPARIB
CBYL719K12301
Phase 3 small_molecule active
Quick answer
PACLITAXEL, ALPELISIB, DOXORUBICIN HYDROCHLORIDE, OLAPARIB, ALPELISIB, OLAPARIB for Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active